南方医科大学学报

南方医科大学学报 ›› 2013, Vol. 33 ›› Issue (12): 1833-.

• • 上一篇    下一篇

英夫利昔单抗治疗炎症性肠病的疗效及影响因素分析

周有连，陈烨   

  • 出版日期:2013-12-20 发布日期:2013-12-20

Efficacy of infliximab in treatment on inflammatory bowel disease and factors affecting
the therapeutic effect

  • Online:2013-12-20 Published:2013-12-20

PDF

1472

摘要： 目的在炎症性肠病治疗过程中，对于传统药物治疗无效或不良反应明显的难治性病例及“降阶梯治疗”方案，生物制剂英
夫利昔单抗已经充分显示了其优越性和安全性，为使临床医生更好的处理炎症性肠病患者，国内外相继出台了2010 年欧洲
ECCO指南、2011年伦敦共识意见及2012年中国共识意见。本文结合国内外最新炎症性肠病诊疗共识，对英夫利昔单抗治疗
炎症性肠病的疗效及影响因素做一综述。

Abstract: Objective Infliximab has shown its superiority and safety in the treatment of inflammatory bowel disease (IBD) that
failed to respond to traditional medical therapy, in refractory cases with obvious adverse reactions, and in "top-down therapy".
For standardized and effective management of IBD, experts worldwide have consecutively issued the 2010 European ECCO
guide, 2011 London consensus, and 2012 Chinese consensus. In this paper, based on the latest expert consensus worldwide, we
reviewed the efficacy of infliximab treatment on IBD and the factors affecting its therapeutic effect.